Empire Genomics

Empire Genomics operates as a specialized biotechnology firm, focusing on the design and production of molecular probes for cancer research and diagnostics. Founded in 2006 by Dr. Norma J. Nowak, a distinguished researcher who contributed to the Human Genome Project, the company emerged from research initiated at the Roswell Park Comprehensive Cancer Center in Buffalo, New York. Dr. Nowak's extensive background in human genomics, including her work on mapping the human genome and identifying genes related to heritable disorders, directly shaped the company's scientific foundation. Her research was pivotal in developing technologies like array CGH, a method for detecting DNA copy number variations in tumor cells, which became a core competency for the company.

The company's business model centers on selling a comprehensive catalog of molecular diagnostic products and services to a global clientele that includes clinical laboratories, research institutions, and biopharmaceutical companies. The core product offering consists of an extensive portfolio of Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) probes. These tools are critical for detecting specific genetic abnormalities—such as gene fusions, amplifications, and deletions—that are instrumental in diagnosing cancers and guiding personalized treatment strategies. Revenue is generated through the direct sale of these cataloged probes, ancillary reagents, and custom assay development services tailored to specific client needs. The company leverages a global distribution network to reach its international markets.

A significant milestone in the company's history was its acquisition by Biocare Medical in November 2022. This strategic move integrated Empire Genomics' molecular biomarker portfolio with Biocare's automated immunohistochemistry (IHC) and FISH instrumentation, aiming to enhance cancer diagnostic capabilities. Prior to its acquisition, the company had secured approximately $3.3 million in funding over several rounds and had itself acquired ID Labs in 2015 to expand its offerings. The company's technology and products have been referenced in over 500 peer-reviewed scientific publications, underscoring their impact on genetic research and patient care.

Keywords: molecular diagnostics, FISH probes, cancer research, genomic products, precision medicine, cytogenetics, biomarker research, CISH probes, custom assay development, oncology diagnostics, genetic testing, human genome, Roswell Park, molecular probes, Biocare Medical, Norma J. Nowak, genomic analysis, cancer diagnostics, personalized treatment, genetic abnormalities